350 related articles for article (PubMed ID: 36510321)
1. Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer's disease continuum.
Gobom J; Benedet AL; Mattsson-Carlgren N; Montoliu-Gaya L; Schultz N; Ashton NJ; Janelidze S; Servaes S; Sauer M; Pascoal TA; Karikari TK; Lantero-Rodriguez J; Brinkmalm G; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
Mol Neurodegener; 2022 Dec; 17(1):81. PubMed ID: 36510321
[TBL] [Abstract][Full Text] [Related]
2. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identification.
Barthélemy NR; Bateman RJ; Hirtz C; Marin P; Becher F; Sato C; Gabelle A; Lehmann S
Alzheimers Res Ther; 2020 Mar; 12(1):26. PubMed ID: 32183883
[TBL] [Abstract][Full Text] [Related]
4. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
[TBL] [Abstract][Full Text] [Related]
5. MAPT R406W increases tau T217 phosphorylation in absence of amyloid pathology.
Sato C; Mallipeddi N; Ghoshal N; Wright BA; Day GS; Davis AA; Kim AH; Zipfel GJ; Bateman RJ; Gabelle A; Barthélemy NR
Ann Clin Transl Neurol; 2021 Sep; 8(9):1817-1830. PubMed ID: 34342183
[TBL] [Abstract][Full Text] [Related]
6. Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys Aβ(1-42), pTau and tTau CSF immunoassays.
Blennow K; Shaw LM; Stomrud E; Mattsson N; Toledo JB; Buck K; Wahl S; Eichenlaub U; Lifke V; Simon M; Trojanowski JQ; Hansson O
Sci Rep; 2019 Dec; 9(1):19024. PubMed ID: 31836810
[TBL] [Abstract][Full Text] [Related]
7. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
[TBL] [Abstract][Full Text] [Related]
8. CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts.
Hansson O; Seibyl J; Stomrud E; Zetterberg H; Trojanowski JQ; Bittner T; Lifke V; Corradini V; Eichenlaub U; Batrla R; Buck K; Zink K; Rabe C; Blennow K; Shaw LM; ;
Alzheimers Dement; 2018 Nov; 14(11):1470-1481. PubMed ID: 29499171
[TBL] [Abstract][Full Text] [Related]
9. Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer's Disease.
Lantero-Rodriguez J; Salvadó G; Snellman A; Montoliu-Gaya L; Brum WS; Benedet AL; Mattsson-Carlgren N; Tideman P; Janelidze S; Palmqvist S; Stomrud E; Ashton NJ; Zetterberg H; Blennow K; Hansson O
Mol Neurodegener; 2024 Feb; 19(1):19. PubMed ID: 38365825
[TBL] [Abstract][Full Text] [Related]
10. CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer's disease.
Barthélemy NR; Saef B; Li Y; Gordon BA; He Y; Horie K; Stomrud E; Salvadó G; Janelidze S; Sato C; Ovod V; Henson RL; Fagan AM; Benzinger TLS; Xiong C; Morris JC; Hansson O; Bateman RJ; Schindler SE
Nat Aging; 2023 Apr; 3(4):391-401. PubMed ID: 37117788
[TBL] [Abstract][Full Text] [Related]
11. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
12. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes.
Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D
Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545
[TBL] [Abstract][Full Text] [Related]
13. Development of immunoprecipitation - two-dimensional liquid chromatography - mass spectrometry methodology as biomarker read-out to quantify phosphorylated tau in cerebrospinal fluid from Alzheimer disease patients.
Bijttebier S; Theunis C; Jahouh F; Martins DR; Verhemeldonck M; Grauwen K; Dillen L; Mercken M
J Chromatogr A; 2021 Aug; 1651():462299. PubMed ID: 34107398
[TBL] [Abstract][Full Text] [Related]
14. Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease.
Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Kim SE; Lee BS; Kim GJ; Yu JS; Lim K; Kang SM; Park YH; Youn YC; An SSA; Kim S
Alzheimers Res Ther; 2017 Dec; 9(1):98. PubMed ID: 29246249
[TBL] [Abstract][Full Text] [Related]
15. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
[TBL] [Abstract][Full Text] [Related]
16. Comparison of cerebrospinal fluid, plasma and neuroimaging biomarker utility in Alzheimer's disease.
Meeker KL; Luckett PH; Barthélemy NR; Hobbs DA; Chen C; Bollinger J; Ovod V; Flores S; Keefe S; Henson RL; Herries EM; McDade E; Hassenstab JJ; Xiong C; Cruchaga C; Benzinger TLS; Holtzman DM; Schindler SE; Bateman RJ; Morris JC; Gordon BA; Ances BM
Brain Commun; 2024; 6(2):fcae081. PubMed ID: 38505230
[TBL] [Abstract][Full Text] [Related]
17. Normalization of CSF pTau measurement by Aβ
Guo T; Korman D; La Joie R; Shaw LM; Trojanowski JQ; Jagust WJ; Landau SM;
Alzheimers Res Ther; 2020 Aug; 12(1):97. PubMed ID: 32799929
[TBL] [Abstract][Full Text] [Related]
18. N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases.
Snellman A; Lantero-Rodriguez J; Emeršič A; Vrillon A; Karikari TK; Ashton NJ; Gregorič Kramberger M; Čučnik S; Paquet C; Rot U; Zetterberg H; Blennow K
Brain; 2022 Aug; 145(8):2834-2848. PubMed ID: 35311972
[TBL] [Abstract][Full Text] [Related]
19. Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios.
Janelidze S; Barthélemy NR; He Y; Bateman RJ; Hansson O
JAMA Neurol; 2023 May; 80(5):516-522. PubMed ID: 36987840
[TBL] [Abstract][Full Text] [Related]
20. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
